Pacific Biosciences Of California (PACB) Net Cash Flow (2010 - 2026)

Pacific Biosciences Of California has reported Net Cash Flow for 17 years, with the latest figure at -$7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 335.73% year-over-year to -$7.4 million; the trailing twelve-month figure through Mar 2026 stood at -$2.9 million (up 84.63% YoY), and the FY2025 full-year result was $7.7 million, up 106.13% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$7.4 million, down from $7.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $176.4 million in Q3 2023, with the low at -$205.7 million in Q4 2023.
• Average Net Cash Flow over 5 years is -$24.0 million, with a median of -$6.0 million recorded in 2022.
• Peak annual rise in Net Cash Flow reached 3033.48% in 2023, while the deepest fall reached 1096.02% in 2023.
• Tracing PACB's Net Cash Flow over 5 years: stood at $20.7 million in 2022, then tumbled by 1096.02% to -$205.7 million in 2023, then soared by 89.01% to -$22.6 million in 2024, then jumped by 130.78% to $7.0 million in 2025, then plunged by 206.25% to -$7.4 million in 2026.
• The last three Net Cash Flow figures came in at -$7.4 million (Q1 2026), $7.0 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.

Peer Comparison